Drug Delivery Business

First patients enrolled in trial for Boston Scientific’s SpaceOAR Vue hydrogel

By

Boston ScientificGenesisCare announced today that it enrolled the first patients in a trial for Boston Scientific’s (NYSE:BSX) SpaceOAR Vue hydrogel.

Boston Scientific’s SpaceOAR Vue hydrogel will be evaluated in the SABRE trial, sponsored by Boston Scientific, for prostate cancer patients receiving stereotactic body radiation therapy (SBRT).

Get the full story at our sister site, MassDevice.

IN CASE YOU MISSED IT

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.